Your browser doesn't support javascript.
loading
Golimumab: clinical update on its use for ulcerative colitis.
Gilardi, D; Fiorino, G; Allocca, M; Bravatà, I; Danese, S.
Afiliación
  • Gilardi D; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Fiorino G; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Allocca M; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Bravatà I; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Danese S; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. sdanese@hotmail.com.
Drugs Today (Barc) ; 51(3): 171-84, 2015 Mar.
Article en En | MEDLINE | ID: mdl-25876561
Monoclonal antibodies directed against tumor necrosis factor alpha (anti-TNF-α agents) have dramatically changed the therapeutical approach to inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. A new anti-TNF drug, golimumab, has recently been approved for patients with moderate to severe ulcerative colitis. Its efficacy has been demonstrated by preclinical and clinical studies and the drug showed an efficacy and safety profile in line with the other anti-TNF agents, such as infliximab and adalimumab. This review gives an overview on golimumab in the treatment of moderate to severe ulcerative colitis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Colitis Ulcerosa / Antiinflamatorios no Esteroideos / Factor de Necrosis Tumoral alfa / Anticuerpos Monoclonales Límite: Animals / Humans Idioma: En Revista: Drugs Today (Barc) Asunto de la revista: MEDICINA OCUPACIONAL / SAUDE AMBIENTAL Año: 2015 Tipo del documento: Article País de afiliación: Italia Pais de publicación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Colitis Ulcerosa / Antiinflamatorios no Esteroideos / Factor de Necrosis Tumoral alfa / Anticuerpos Monoclonales Límite: Animals / Humans Idioma: En Revista: Drugs Today (Barc) Asunto de la revista: MEDICINA OCUPACIONAL / SAUDE AMBIENTAL Año: 2015 Tipo del documento: Article País de afiliación: Italia Pais de publicación: España